This website uses cookies to give you the best user experience. If you continue
without changing your settings we'll assume you are happy to receive all RSC cookies.
You can change your cookie settings by navigating to our Privacy and Cookies page and following the instructions. These instructions
are also obtainable from the privacy link at the bottom of any RSC page.
Institute for Molecular Bioscience, The University of Queensland, St Lucia 4072, Queensland, Australia
E-mail: p.alewood@imb.uq.edu.au
; Tel: +3346 2982
b
Australian Centre for Blood Diseases, Monash University, Alfred Medical Research & Education Precinct (AMREP), Melbourne 3004, Australia
E-mail: rob.andrews@monash.edu
; Fax: +03-99030228
; Tel: +03-99030136
Org. Biomol. Chem., 2012,10, 5791-5794
DOI:
10.1039/C2OB25133G
Received
18 Jan 2012,
Accepted
26 Apr 2012
First published online
26 Apr 2012
A dual-pharmacophoric peptide was engineered by grafting the integrin binding RGD motif between the C- and N-termini of a disulfide-rich noradrenaline transporter inhibiting χ-conotoxin resulting in a stable backbone cyclized peptide. The construct maintained two independent biological activities and showed increased plasma stability with no adverse effects observed following administration to rats, highlighting the potential value of pharmacophore grafting into constrained peptide scaffolds.
Fetching data from CrossRef. This may take some time to load.
Organic & Biomolecular Chemistry
- Information Point